Thus, consistent with our in vitro data, DT-061 can modulate the phosphorylation and expression of 4E-BP1 in tumor cells in vivo, supporting the clinical potential of PP2A-based therapeutics for restoration of translational control in cancer. This evidence concerns the gene PTPA and neoplasm.